Teva abandons Ajovy trial for cluster headaches
A Phase III study found that the primary endpoint for weekly average number of cluster headache attacks during the four-week treatment period is unlikely to be met.
Read More
Tag: CGRP
Allergan files anti-CGRP migraine drug in the US
US regulators have accepted for review Allergan’s application to market ubrogepant for the acute treatment of migraine.
Read More
Lilly’s Emgality wins first nod for migraine prevention
The US Food and Drug Administration have green-lighted use of Eli Lilly’s non-opioid pain drug Emgality for the prevention of migraine.
Read More
Teva pulls fremanezumab cluster headaches trial
Teva is discontinuing a late-stage trial assessing the efficacy of its experimental anti-CGRP therapy fremanezumab in reducing cluster headaches.
Read More
Allergan’s experimental migraine drug hits trial targets
Allergan says its CGRP receptor antagonist atogepant has hit its primary target in a Phase IIb/III trial assessing its efficacy in preventing episodic migraine.
Read More
Amgen, Novartis’ migraine therapy impresses again
Amgen and Novartis’ closely watched experimental migraine therapy Aimovig has impressed again in late stage trials, this time hitting targets in patients for which other preventative treatments failed to work or weren’t tolerated.
Read More
Trial success for Allergan’s anti-CGRP migraine drug
The first of two pivotal Phase III clinical trials evaluating Allergan’s experimental anti-CGRP migraine drug ubrogepant has met its key goal.
Read More
Lilly files anti-CGRP drug for migraine
US regulators have accepted for review Eli Lilly’s investigational non-opioid pain drug galcanezumab for the prevention of migraine.
Read More
Stellar results for Novartis, Teva anti-CGRP migraine drugs
The New England Journal of Medicine has published two separate studies showing that CGRP-targeting therapies – namely Novartis’ erenumab and Teva’s fremanezumab – significantly cut the number of headache days in patients with episodic or chronic migraine, respectively.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
